Akeso
Tracked across 4 events · 52 articles · First seen May 25, 2026 · Last active Sep 13, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Akeso received NMPA approval for Gumokimab, strengthening its autoimmune disease portfolio and global competitiveness. This approval is a significant milestone for the company, enhancing its market position and offering a new treatment option for psoriasis patients.
Jun 12, 2026 · 7 articles
Tech
Impact: Akeso is the developer and sponsor of the Phase II study, and this milestone advances its IO2.0 + ADC2.0 strategy. The company's pipeline and clinical progress are central to its valuation and growth prospects.
Aug 10, 2026 · 6 articles
Tech
Akeso announced that a pre-specified interim analysis of overall survival (OS) in the Phase III HARMONi-2 (AK112-303) trial, assessed by the Independent Data Monitoring Committee, met the key secondary OS endpoint. Ivonescimab, Akeso's first-in-class PD-1/VEGF…
Impact: Akeso is the sponsor and primary beneficiary of the HARMONi-2 trial; the positive OS results reinforce ivonescimab's best-in-class potential and support its commercial and licensing outlook.
Jul 20, 2026 · 6 articles
Tech
Impact: Akeso announced that over 40 clinical studies of its oncology portfolio, including data on cadonilimab and ivonescimab, were presented at the 2026 ASCO Annual Meeting, with one Late-Breaking Abstract selected for a Plenary Session.
May 25, 2026 · 33 articles
95
Akeso met overall survival endpointIvonescimab HARMONi-2...
85
Akeso presented overall survival resultsIvonescimab HARMONi-2...
60
Akeso met progression-free survival endpointIvonescimab HARMONi-2...
55
China approved ivonescimab indication AkesoIvonescimab HARMONi-2...
ERGEN INTELLIGENCE
Track Akeso live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard